xermelo
serb sas - telotristat etiprate - carcinoid tumor; neuroendocrine tumors - Önnur meltingarfæri og umbrotsefni - xermelo er ætlað til meðferðar við niðurgangi karcinoid heilkenni í samsettri meðferð með sómatostatínhliðstæðum (ssa) meðferð hjá fullorðnum sem ekki hafa fullnægjandi stjórn á ssa meðferð.
sandostatin stungulyf, lausn 100 míkróg/ml
novartis healthcare a/s - octreotidum inn - stungulyf, lausn - 100 míkróg/ml
sandostatin stungulyf, lausn 50 míkróg/ml
novartis healthcare a/s - octreotidum inn - stungulyf, lausn - 50 míkróg/ml
upstaza
ptc therapeutics international limited - eladocagene exuparvovec - aminósýra efnaskipti, innfæddir villur - enzymes, other alimentary tract and metabolism products - upstaza is indicated for the treatment of patients aged 18 months and older with a clinical, molecular, and genetically confirmed diagnosis of aromatic l amino acid decarboxylase (aadc) deficiency with a severe phenotype (see section 5.
sumatriptan apofri filmuhúðuð tafla 50 mg
evolan pharma ab - sumatriptanum súkkínat - filmuhúðuð tafla - 50 mg
sumatriptan bluefish tafla 100 mg
bluefish pharmaceuticals ab - sumatriptanum súkkínat - tafla - 100 mg
haiprex tafla 1 g
viatris aps - methenaminum hippúrat - tafla - 1 g
trilafon dekanoat (trilafon dekanoat) stungulyf, lausn 108 mg/ml
orion corporation - perphenazinum dekanóat - stungulyf, lausn - 108 mg/ml
imigran nefúði, lausn 20 mg/skammt
glaxosmithkline pharma a/s - sumatriptanum inn - nefúði, lausn - 20 mg/skammt
imigran stungulyf, lausn 12 mg/ml
glaxosmithkline pharma a/s - sumatriptanum súkkínat - stungulyf, lausn - 12 mg/ml